Suloctidil
 | |
| Clinical data | |
|---|---|
| ATC code | |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.053.920 |
| Chemical and physical data | |
| Formula | C20H35NOS |
| Molar mass | 337.563 g·mol−1 |
| (verify) | |
Suloctidil was a sulfer-containing aminoalcohol that was brought to market in the early 1970s as a vasodilator by Continental Pharma, a Belgian company.[1]: 118–121 [2]
Continental was bought by Monsanto in 1984, primarily on the promise of sales of suloctidil, which was approved in Europe at the time, but not in the US.[3] However, in 1985 Monsanto halted development and withdrew the drug worldwide following reports of liver toxicity.[4]: 251
References
- ^ Josef Hladovec. Antithrombotic Drugs in Thrombosis Models. CRC Press, 1989 ISBN 9780849351624
- ^ Roncucci R et al. Potential antilipolytic activity of suloctidil. Naturwissenschaften. 1975 Mar;62(3):141-2 PMID 1240601. Paper cites Belgian patent 739678
- ^ Staff, The Pink Sheet. No vember 5 1984 Monsanto's $150 mil. Life Sciences Research Center
- ^ Department of Economic and Social Affairs of the United Nations Secretariat Consolidated List of Products Whose Consumption and/or Sale Have Been Banned, Withdrawn, Severely Restricted or not Approved by Governments Twelfth Issue: Pharmaceuticals United Nations – New York, 2005
 | This drug article relating to the cardiovascular system is a stub. You can help Wikipedia by expanding it. |